Article by NextAccel | May 13, 2025 | 15min read
McKinsey’s analysis of 60+ MedTech firms reveals a critical competitive advantage: companies with advanced commercial capabilities achieve 1.4x higher CAGR than those with average capabilities. Yet most organizations continue to underperform through misaligned GTM models, AI-deficient sales processes, and disconnected financial operations-converting promising strategies into stalled execution and unrealized value.
In today’s capital-constrained environment where margin pressures intensify, CEOs must aggressively close this execution gap. This requires systematically integrating commercial, sales, and finance functions under a unified operating model that converts strategic intent into measurable market impact—the difference between industry leadership and mediocre performance in an increasingly competitive landscape.
Figure 1
MedTech Growth Performance Multiplier
Key Insights:
Companies with advanced commercial
capabilities achieve 1.4x faster growth
than competitors with average capabilities.
Figure 2
Execution Capability Gap
Key Insights:
The largest execution gapsexists
in sales enablement (44%) and cross
functional alignment (41%)
For MedTech CEOs, the data is clear: execution—not strategy—is the primary growth bottleneck. Companies with advanced commercial capabilities grow 1.4x faster than their peers, yet significant execution gaps persist across the industry.
To compete in today’s capital-constrained, margin-pressured market, MedTech leaders must bridge the gap between strategic intent and operational impact by aligning commercial, sales, and finance execution under a unified operating model.
| Strategic Parameters | Actionable Control Levers What CEOs Can Influence Potential Actions |
|---|---|
|
Strategic Parameters |
Implementing Account Based
Marketing (ABM) and aligning sales
with qualified lead generation. |
|
Profitability & Cost Control |
Modernizing operations with AI
and realigning cost structures. |
|
Revenue Resilience |
Creating recurring or re-occurring
revenue streams. |
|
Financial Agility & Capital Allocation |
Adjusting investment priorities
using scenario modeling and
CapEx optimization. |
|
Data & Compliance Readiness |
Fortifying real-time data access
and enterprise cybersecurity
frameworks. |
Alignment Gap
= Missed Growth:
Only 23% of MedTech
firms report strong sales-
marketing collaboration
-a clear growth opportunity.
(Source: McKinsey)
For MedTech CEOs, sales and marketing alignment is a growth multiplier. As buyer journeys grow more complex and sales cycles lengthen, CEOs must unify commercial efforts around clear value narratives and performance-driven execution.
This means leading a shift from siloed outreach to a coordinated go-to-market engine that speaks directly to the needs of providers, payers, and patients. The CEO plays a critical role in ensuring product innovation is matched by messaging precision—turning every market engagement into a lever for trust, differentiation, and revenue acceleration.
ABM for Premium Contracts:
Companies using account-based marketing (ABM) see 171% higher average contract values. (Source: TOPO)
AI Boosts Sales Performance:
Sales teams using AI-assisted lead scoring achieve 46% higher quota attainment. (Source: Emplibot)
Actionable takeaway
Lead generation from top of the Funnel metrics resulting in potential digital transactions need to eventually convert to re-occurring revenues. Invest in targeted account management to drive this re-occurrence and minimize marketing spend to acquire the same customer.
In MedTech, customer churn is more than lost revenue—it’s a threat to long-term profitability due to high acquisition costs and extended sales cycles. For CEOs, retention must be a boardroom priority. That means embedding lifecycle value into the commercial model from day one.
Leading firms are using usage analytics, proactive account management, and outcome-based support to detect risk early and recover at-risk accounts. Post-sale engagement—from onboarding to upgrades and training—must be treated as a growth function, not an afterthought. Recovery isn’t reactive—it’s strategic.
A 5% boost in customer retention can lead to a 25–95% profit increase. (Source: Harvard Business Review)
68% of B2B MedTech buyers cite lack of post-sale engag- ement as their reason for switching vendors. (Source: Forrester)
Repeat Business Wins: 60–70% of retained MedTech customers are more likely to return for additional services. (Source: Definitive Healthcare)
Actionable takeaway
Retention is your most capital-efficient growth lever. Build post-sale value delivery into the DNA of your commercial strategy—because in MedTech, customers aren’t just won, they’re continuously earned.
In MedTech, recurring revenue doesn’t happen by accident—it’s built through intentional account management. CEOs must lead the shift from transactional selling to long-term partnership models, embedding account managers as strategic advisors across the customer lifecycle.
This requires equipping teams with consultative skills, driving digital engagement, and ensuring ongoing value delivery through training, support, and usage analytics. The goal? Maximize customer lifetime value (CLTV), reduce churn, and convert post-sale engagement into a predictable revenue stream.
Repeat Revenue Engine
Companies with mature account management practices generate 70% of revenue from repeat customers.
(Source: Zuora)
CLTV Advantage
Subscription-based MedTech products deliver higher lifetime value than one-time sales.
(Source: Bessemer Venture Partners)
Shifting Models
25% of MedTech firms with connected devices now offer subscription-based pricing for recurring revenue.
(Source: Capgemini)
Actionable takeaway
Recurring revenue is a strategic asset. Make account management a growth function, not a support one, and turn every customer into a compounding revenue source.
Margin Leaders Set the Bar: Top MedTech performers like Intuitive Surgical maintain gross margins of 67%—a benchmark for capital efficiency and pricing power. (Source: Yahoo Finance)
Forecasting Fuels Growth: Organizations using dynamic forecasting models consistently outperform peers in EBITDA growth, driving smarter reinvestment and resilience. (Source: PwC, 2024)
Legacy Systems Drain Liquidity: Healthcare systems still running on outdated financial tech report a 28% drop in days cash on hand—highlighting the cost of inaction. (Source: Kaufman Hall)
Actionable takeaway
To lead with financial agility, MedTech CEOs must modernize forecasting, protect margins, and reallocate capital toward top-line and EBITDA outcomes. Dynamic planning and tech-enabled visibility aren’t just financial hygiene—they’re levers for sustainable growth and investor confidence.
Automation is about accelerating strategic outcomes. By digitizing high-impact workflows across supply chain, billing, and compliance, leaders free up capital and talent for innovation in AI diagnostics, robotics, and precision care.
Top-performing firms are using intelligent automation to reduce cycle times, boost productivity, and de-risk operations. The CEO’s mandate? Prioritize automation that unlocks speed, scalability, and measurable ROI—turning operational efficiency into a competitive edge.
AI-Driven Cost Cuts: Automating workflows with AI and RPA can reduce operational costs by 30–50%, unlocking capital for R&D and innovation in areas like diagnostics and robotic surgery.
(Source: Deloitte)
Smarter Maintenance, Less Downtime: Predictive maintenance powered by AI can reduce equipment downtime by up to 30%, improving manufacturing throughput and quality.
(Source: Frigate.ai)
Supply Chain Intelligence: AI-led inventory optimization helps MedTech firms reduce excess stock while maintaining resilience-balancing 119-293 days of inventory for cost-efficient delivery.
(Source: EY MedTech Pulse)
Actionable takeaway
Prioritize automation initiatives that directly drive speed, scalability, and ROI. Focus on digitizing high-impact workflows-like supply chain, compliance, and maintenance-to free up capital and talent for innovation in AI diagnostics and robotics. In today’s MedTech climate, operational agility isn’t optional-it’s a strategic growth lever.
1. The New Growth Frontiers: Outpatient & Hospital-at-Home (HaH)
Key Insight: The healthcare ecosystem is evolving—shifting from the hospital to more decentralized, cost-efficient models.
Outpatient Surge: Volume growth in ambulatory surgery centers (ASCs) is set to outpace inpatient care by a 5:1 ratio through 2033. Urgent care centers alone now generate $450K more in referral revenue per site than traditional primary care providers.
Hospital-at-Home (HaH): HaH programs reduce 30-day Medicare costs by $1,640 per patient while improving patient outcomes. Projections show a 119% CAGR in HaH by 2029, with early adopters like Mayo Clinic leading the charge.
Actionable Takeaway: MedTech CEOs must redirect capital—allocate 20% of 2026 investments toward outpatient and HaH infrastructure. For every $1M invested, expect $2.3M in incremental revenue over five years, positioning the company at the forefront of the healthcare delivery revolution.
2. Market Sentiment & Recession Risks: Shoring Up Resilience
Key Insight: Economic downturns require agility, diversification, and a focus on value-driven innovations.
Orthopedic Sector Vulnerabilities: Economic recessions often lead to a 20–30% decline in orthopedic valuations. MedTech leaders should diversify revenue streams and focus on sectors less impacted by cyclical downturns, like outpatient care.
Investor Caution: Private equity deals dropped 22% in 2023. To attract investment, MedTech CEOs must emphasize AI-driven cost efficiencies, patent moats, and future-ready innovations that protect long-term margins.
Actionable Takeaway: CEOs should diversify revenue sources through outpatient and connected health solutions to hedge against volatility. Additionally, fostering an AI-driven growth model and reinforcing intellectual property (IP) will safeguard investor confidence and support sustainable profitability in a turbulent market.
FinOps
Strategic Insight: Cloud cost optimization is no longer just a tech issue—it’s a balance-sheet and boardroom imperative.
Align IT infrastructure with sustainability goals by transitioning to greener cloud providers and consolidating workloads.
For every $500K saved, reinvest into AI patent
development to secure future IP advantage.
Target a 30% reduction in cloud spend through cross-functional FinOps teams.
Automate 50% of back-office workflows (finance, HR, compliance) using RPA and intelligent process automation.
Strategic Insight: Automation drives not just cost savings but frees up capital for innovation acceleration.
Redirect operational savings into generative AI trials in high-impact areas like drug discovery, robotic surgery, and diagnostics.
Strategic Insight: Agile GTM frameworks improve responsiveness to pricing shifts, regional demand surges, and care delivery changes.
Diversify channels beyond field sales into digital, platform-based partnerships, and embedded services.
Use AI-powered demand sensing and localized playbooks to reduce time-to-revenue by up to 30%.
If you’re not executing all three, you’re exposed. If you are, you’re positioned to lead.
Schedule a 90-minute strategy session with NextAccel to transform your MedTech growth roadmap using the 3D Growth Engine (Define-Deploy-Deliver). We help MedTech leaders drive EBITDA uplift, enhance Sales Enablement, and optimize Go-To-Market (GTM) strategies. Our actionable plan addresses alignment gaps across GTM, operations, and finance, ensuring growth and accountability within 90 days. NextAccel has delivered measurable results for top MedTech companies, helping them stay on track for long-term success.
Sanjeev K, (CEO of NextAccel )
In 2025, the mandate for MedTech CEOs is to control the controllables and influence the rest. It’s about focusing on what truly matters, like financial agility, strategic sales alignment, and automation. By mastering these critical areas, CEOs can protect their companies from external challenges and ensure consistent growth.
As the healthcare sector shifts toward outpatient and home-based models, only those with a clear and disciplined strategy will lead in the new era. With NextAccel as your strategic partner, you’ll be well-positioned to prioritize what matters most and maximize enterprise value, even in uncertain times.
